Search
  • English
  • 中文
flash1
  • About Us
    • At a Glance
    • History
    • Recognition
    • Management Team
  • Research & Development
    • Oncology
    • Immunology
  • Pipeline
  • Partnership
    • Overview
    • Existing Partnerships
  • News & Publications
    • Press Releases
    • Publications
  • Careers
    • Employment Opportunities
    • Cultural Activities
  • Contacts
Press Releases
06-Mar-2018
HMP Initiates a Phase Ib/II Proof-of-Concept Trial of Epitinib in Glioblastoma in China
13-Feb-2018
HMP Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer
15-Dec-2017
HMP Initiates Fruquintinib U.S. Clinical Trials
31-Oct-2017
HMP Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer
17-Oct-2017
HMP and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification
16-Oct-2017
HMP Reports Preliminary Phase II data on Fruquintinib Combination in First-Line Lung Cancer
12-Oct-2017
Appointment of Director
29-Aug-2017
HMP Initiates a Phase I Clinical Trial of Selective PI3Kδ Inhibitor HMPL 689 in Lymphoma Patients in China
29-Jun-2017
HMP and AstraZeneca Initiate SAVOIR, a Global Phase III Trial of Savolitinib in Papillary Renal Cell Carcinoma
22-Jun-2017
HMP Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China
12345...10...»»
  • Disclaimer
  • Sitemap
    •
    Copyright ©2018 Hutchison MediPharma Limited. All rights reserved.